Therefore, it is clear that 213Bi-PAI2 is an effective and specific radiolabelled agent for ablation of individual PC3 prostate cancer cell in vitro whereas non-targeted cells are spared from the radiotoxicity arising from the alpha radiation. This evidence concerns the gene SERPINB2 and prostate carcinoma.